Genetic tests

Full name Analytes Gene panels Disease Laboratory
CYP2B6*6,*11,*18 genotyping - drug metabolism - Pharmacogenetics CYP2B6 Efavirenz toxicity Centre de Génétique Médicale UCL
CYP2C19*2,*3,*17 genotyping - drug metabolism - Pharmacogenetics CYP2C19 Antidepressant or antipsychotic toxicity or dose selection, Resistance to clopidogrel, Voriconazole toxicity Centre de Génétique Médicale UCL
CYP2C9*2,*3 genotyping - drug metabolism - Pharmacogenetics CYP2C9 Vitamin K antagonists toxicity or dose selection, Oral antidiabetic drugs toxicity or dose selection Centre de Génétique Médicale UCL
SLCO1B1*1b,*5,*15 genotyping (transport protein) - Pharmacogenetics SLCO1B1 Statin toxicity Centre de Génétique Médicale UCL
Resistance to vitamin K antagonists - VKORC1 sequencing (all exons ) - Pharmacogenetics VKORC1 Resistance to vitamin K antagonists, Prediction of resistance to vitamin K antagonists Centre de Génétique Médicale UCL
Vitamin K antagonists toxicity or dose selection - VKORC1 genotyping (-1639G>A + 1173C>T) - Pharmacogenetics VKORC1 Vitamin K antagonists toxicity or dose selection, Prediction of toxicity or dose selection of vitamin K antagonists Centre de Génétique Médicale UCL
Resistance to clopidrogel - PON1 genotyping (Q192R) - Pharmacogenetics Centre de Génétique Médicale UCL
5-fluorouracil (5-FU) toxicity - DPYD sequencing (all exons) - Pharmacogenetics DPYD 5-fluorouracil toxicity Centre de Génétique Médicale UCL
Response to antiviral treatment in hepatitis C - IL28B genotyping (rs8099917 (T>G) + rs12979860 (C>T)) - Pharmacogenetics IFNL3 Response to antiviral treatment in hepatitis C Centre de Génétique Médicale UCL
CYP3A4*22 genotyping - drug metabolism - Pharmacogenetics CYP3A4 Tacrolimus dose selection Centre de Génétique Médicale UCL
CYP2D6 genotyping (full gene sequencing + pseudogene and CNV analysis)- drug metabolism - Pharmacogenetics CYP2D6 Codeine toxicity, Resistance to tamoxifene, Antidepressant or antipsychotic toxicity or dose selection Centre de Génétique Médicale UCL
TPMT and NUDT15 sequencing - Pharmacogenetics TPMT, NUDT15 Cisplatin toxicity, Azathioprine or 6-mercatopurine toxicity or dose selection Centre de Génétique Médicale UCL
CYP3A5*3,(*6) genotyping - drug metabolism - Pharmacogenetics CYP3A5 Tacrolimus dose selection Centre de Génétique Médicale UCL
Gilbert disease - UGT1A1*28,*36,*37 {A(TA)nTAA} + *6 genotyping - Pharmacogenetics UGT1A1 Transient familial neonatal hyperbilirubinemia, Irinotecan toxicity, Raltegravir toxicity Centre de Génétique Médicale UCL
Breast and Ovarian Cancer, HBOC, Hereditary Breast and ovarian cancer - UGent Hereditary breast cancer, Hereditary breast and/or ovarian cancer syndrome Centrum Medische Genetica - UZ Gent
Somatic analysis of the BRCA genes in the context of ovarian cancer treatment (2 genes) BRCA1, BRCA2 Centrum Medische Genetica - UZ Gent
Abacavir toxicity (HLA-B*57:01 genotyping) - Pharmacogenetics HLA-B Abacavir toxicity Centrum Medische Genetica - UZ Gent
Somatic analysis of the BRCA genes in the context of ovarian cancer treatment (2 genes) BRCA1, BRCA2 Centre de Génétique-Institut de Pathologie et de Génétique (IPG)
Thiopurine S-Methyltransferase deficiency - TPMT genotyping c.238G>C (rs1800462); c.460G>A (rs1800460); c.719A>G (rs1142345)) - Pharmacogenetics TPMT Azathioprine or 6-mercatopurine toxicity or dose selection Centre de Génétique-Institut de Pathologie et de Génétique (IPG)
Thiopurine S-Methyltransferase deficiency - TPMT genotyping c.238G>C (rs1800462); c.460G>A (rs1800460); c.719A>G (rs1142345)) - Pharmacogenetics TPMT Azathioprine or 6-mercatopurine toxicity or dose selection Centre de Génétique Humaine - Erasme ULB
Download XLSX
Download PDF